Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

De-Escalation or Discontinuation of TKI in Patients with Chronic Myeloid Leukemia:a Multicentral,Open-Lable, Prospective Trial in China

Jie Luo, Yaxian Tan, Xuan Zhou, PhD, Liu Xiaoli, MD, Qifa Liu, MD, Na Xu

Blood (2020) 136 (Supplement 1): 6.

https://doi.org/10.1182/blood-2020-139413

Published: 2020

Journal Articles

Efficacy of Early Convert to Dasatinib in Chronic Myeloid Leukemia Patients Who Inresponse or Intolerance to Imatinib

Liu Liang, Na Xu, PhD, Xuan Zhou, PhD, Huang JiXian, Chen Chen, Lin Tong, Wu wan-Er, Changxin Yin, Qifa Liu, MD, Liu Xiaoli, MD

Blood (2018) 132 (Supplement 1): 5430.

https://doi.org/10.1182/blood-2018-99-114120

Published: 2018

Journal Articles

The Clinical Characteristics and Efficacy of Chronic Myeloid Leukemia Patients with T315I Mutation

Chen Chen, Na Xu, PhD, Wu WanEr, Liu Liang, Xuan Zhou, PhD, Huang JiXian, Yin Changxin, Rui Cao, Qifa Liu, MD, Liu Xiaoli, MD

Blood (2018) 132 (Supplement 1): 5433.

https://doi.org/10.1182/blood-2018-99-114113

Published: 2018

Journal Articles

Dasatinib Versus Imatinib in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Not Achieved an Optimal Response to 3 Months of Imatinib Therapy: Dascern

Jorge E. Cortes, MD, Qian Jiang, MD, Jianxiang Wang, MD, Jianyu Weng, MD, Huanling Zhu, MD, Liu Xiaoli, MD, Andreas Hochhaus, MD, Dong-Wook Kim, MD PhD, Jerald Radich, MD, Michael R. Savona, MD, Patricia Martin Regueira, MD, Oumar Sy, PhD, Renuka Gurnani, BA, Giuseppe Saglio

Blood (2018) 132 (Supplement 1): 788.

https://doi.org/10.1182/blood-2018-99-111978

Published: 2018

Journal Articles

PKM2 Mediates Chronic Myeloid Leukemia Imatinib Resistance By Regulating Glycolysis Energy Metabolism

Lin Tong, Na Xu, PhD, Xuan Zhou, PhD, Jixian Huang, Wu wan-Er, Chen Chen, Liu Liang, Qifa Liu, MD, Liu Xiaoli, MD

Blood (2018) 132 (Supplement 1): 1724.

https://doi.org/10.1182/blood-2018-99-113960

Published: 2018

Journal Articles

Front-Line Treatment with Second-Generation Tyrosine Kinase Inhibitors Following By Allo-Transplantation Benefits Patients with Better Survival Inph-Positive Acute Lymphoblastic Leukemia

Guo-Pan Yu, MD, Fang Chen, Dan Xu, Changxin Yin, Qifa Liu, Jing Sun, MD, Zhiping Fan, Qiang Wang, PhD, Liu Xiaoli, MD, Qianli Jiang, MD PhD

Blood (2017) 130 (Supplement 1): 4522.

https://doi.org/10.1182/blood.V130.Suppl_1.4522.4522

Published: 2017

Journal Articles

Inhibition of Atg7 Enhances Mesenchymal Stem Cells Regulates Energy Metabolism Coupling to Overcome Drug Resistance in Chronic Myeloid Leukemia

Na Xu, PhD, Yangqing Lan, Ziyuan Lu, PhD, Xuan Zhou, PhD, Jixian Huang, Bolin He, Jing Sun, MD, Liu Xiaoli, MD

Blood (2017) 130 (Supplement 1): 5244.

https://doi.org/10.1182/blood.V130.Suppl_1.5244.5244

Published: 2017

Journal Articles

Tumor-Derived LOXL2 Is Highly Expressed in Myelofibrosis and Activating Mesenchymal Stem Cells Differentiate into Cancer Associated Fibroblasts In Vitro

Na Xu, PhD, Chengyun Pan, Xuan Zhou, PhD, Jixian Huang, Yangqing Lan, Bolin He, Jing Sun, MD, Liu Xiaoli, MD

Blood (2017) 130 (Supplement 1): 5289.

https://doi.org/10.1182/blood.V130.Suppl_1.5289.5289

Published: 2017

Journal Articles

Chidamide, a Novel Histone Deacetylase Inhibitor, Combined with Imatinib Induces Synthetic Lethality in Drug-Resistant Chronic Myeloid Leukemia

Bolin He, Qiang Wang, PhD, Na Xu, PhD, Ziyuan Lu, PhD, Chengyun Pan, Jing Sun, MD, Hongsheng Zhou, PhD, Liu Xiaoli, MD

Blood (2017) 130 (Supplement 1): 4990.

https://doi.org/10.1182/blood.V130.Suppl_1.4990.4990

Published: 2017

Journal Articles

Tumor-Associated Macrophages Maybe Associated with Acute Myeloid Leukemia Survival and Prognosis

Xuan Zhou, PhD, Na Xu, PhD, Xueyan Sun, Tong Lin, Zhiping Fan, Rui Cao, Qifa Liu, MD, Jing Sun, MD, Liu Xiaoli, MD

Blood (2017) 130 (Supplement 1): 5090.

https://doi.org/10.1182/blood.V130.Suppl_1.5090.5090

Published: 2017

Journal Articles

EphB4/ephrinB2 ephrinB1 Interaction Mediated Chronic Myelogenous Leukemia Mesenchymal Stromal Cells Osteogenic Differentiation in Vitro and In Vivo

Li Lin, MD, Xu Na, PhD, Jiang Zhiwu, Lu Qisi, Zhou Xuan, Lu Ziyuan, Huang Jixian, MD, Li Yuling, He Bolin, Pan Chengyun, Li Peng, Liu Xiaoli, MD

Blood (2016) 128 (22): 1901.

https://doi.org/10.1182/blood.V128.22.1901.1901

Published: 2016

Journal Articles

CDKN2 Gene Deletion Impair Prognosis in Adult Ph+ Acute Lymphoblastic Leukemia Even in Tyrosine Kinase Inhibitors Era

Na Xu, MD, Yuling Li, Xuan Zhou, MD, Hongqian Zhu, MD, Lin Li, Qisi Lu, Rui Cao, Huan Li, Qifa Liu, MD, Liu Xiaoli, MD

Blood (2015) 126 (23): 2439.

https://doi.org/10.1182/blood.V126.23.2439.2439

Published: 2015

Journal Articles

LOXL2 Highly-Expressed Induce the Transition of Stromal Cells into Cancer-Associated Fibroblasts Which Maybe Involve in Myeloproliferative Neoplasms Progession

Na Xu, MD, Yuling Li, Xuan Zhou, MD, Lin Li, Qisi Lu, Qifa Liu, MD, Liu Xiaoli, MD

Blood (2015) 126 (23): 5207.

https://doi.org/10.1182/blood.V126.23.5207.5207

Published: 2015

Journal Articles

EphB4/EphrinB2 Contributes to Imatinib Resistance in Chronic Myeloid Leukemia Involved in Cytoskeletal Proteins

Lin Li, Na Xu, MD, Xuan Zhou, MD, Yuling Li, Qisi Lu, Ziyuan Lu, Jixian Huang, Bolin He, Chengyun Pan, Qifa Liu, MD, Liu Xiaoli, MD

Blood (2015) 126 (23): 5135.

https://doi.org/10.1182/blood.V126.23.5135.5135

Published: 2015

Journal Articles

EphB4/ephrinB2 Interaction Mediate Chronic Myelogenous Leukemia Mesenchymal Stromal Cells Spreading and Osteogenic Differentiation

Lin Li, Na Xu, MD, Xuan Zhou, MD, Jixian Huang, Yuling Li, Qisi Lu, Bolin He, Chengyun Pan, Qifa Liu, MD, Liu Xiaoli, MD

Blood (2015) 126 (23): 4772.

https://doi.org/10.1182/blood.V126.23.4772.4772

Published: 2015

Journal Articles

CDKN2 Gene Deletion As Poor Prognosis Predictor Involving in the Progression of Adult B-Lineage Acute Lymphoblastic Leukemia Patients

Yuling Li, Na Xu, MD, Xuan Zhou, MD, Jixian Huang, Lin Li, Qisi Lu, Ziyuan Lu, Bolin He, Chengyun Pan, Qifa Liu, MD, Liu Xiaoli, MD

Blood (2015) 126 (23): 4806.

https://doi.org/10.1182/blood.V126.23.4806.4806

Published: 2015

Journal Articles

Therapeutic Immune Monitoring of Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors: Focus on CD4 + CD25 + t Cells

Ziyuan Lu, Na Xu, MD, Xuan Zhou, MD, Guanlun Gao, Lin Li, Jixian Huang, Yuling Li, Qisi Lu, Bolin He, Chengyun Pan, Liu Xiaoli, MD

Blood (2015) 126 (23): 4036.

https://doi.org/10.1182/blood.V126.23.4036.4036

Published: 2015

Journal Articles

Inhibition of Siah2 Ubiquitin Ligase By Vitamin K3 Attenuates Hypoxia and Blocks K562-R Cells Resistance

Na Xu, Yajuan Xiao, Xuan Zhou, Lin Li, Fen Huang, Bing Xu, MD, Liu Xiaoli, MD

Blood (2014) 124 (21): 5214.

https://doi.org/10.1182/blood.V124.21.5214.5214

Published: 2014

Journal Articles

Interferon Alpha May Improve the prognosis of Advanced Myeloproliferative Neoplasm Patients with JAK2V617F Mutations

Liu Xiaoli, MD, Li Ding, Na Xu, Bintao Huang, Xuan Zhou, Lu Qisi, Jixian Huang

Blood (2014) 124 (21): 5547.

https://doi.org/10.1182/blood.V124.21.5547.5547

Published: 2014

Journal Articles

The Prevalent, Features and Prognostic Impact of Deletion p16 in Patients with Adult Acute Lymphoblastic Leukemia

Na Xu, Yulin Li, Xuan Zhou, Liu Xiaoli, MD, Hongsheng Zhou, MDPhD, Fen Huang, Bing Xu, MD, Qifa Liu, MD, Jing Sun, MD, Ru Feng, MD, Fanyi Meng, MD

Blood (2014) 124 (21): 5351.

https://doi.org/10.1182/blood.V124.21.5351.5351

Published: 2014

NARROW

De-Escalation or Discontinuation of TKI in Patients with Chronic Myeloid Leukemia:a Multicentral,Open-Lable, Prospective Trial in China

Efficacy of Early Convert to Dasatinib in Chronic Myeloid Leukemia Patients Who Inresponse or Intolerance to Imatinib

The Clinical Characteristics and Efficacy of Chronic Myeloid Leukemia Patients with T315I Mutation

Dasatinib Versus Imatinib in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Not Achieved an Optimal Response to 3 Months of Imatinib Therapy: Dascern

PKM2 Mediates Chronic Myeloid Leukemia Imatinib Resistance By Regulating Glycolysis Energy Metabolism

Front-Line Treatment with Second-Generation Tyrosine Kinase Inhibitors Following By Allo-Transplantation Benefits Patients with Better Survival Inph-Positive Acute Lymphoblastic Leukemia

Inhibition of Atg7 Enhances Mesenchymal Stem Cells Regulates Energy Metabolism Coupling to Overcome Drug Resistance in Chronic Myeloid Leukemia

Tumor-Derived LOXL2 Is Highly Expressed in Myelofibrosis and Activating Mesenchymal Stem Cells Differentiate into Cancer Associated Fibroblasts In Vitro

Chidamide, a Novel Histone Deacetylase Inhibitor, Combined with Imatinib Induces Synthetic Lethality in Drug-Resistant Chronic Myeloid Leukemia

Tumor-Associated Macrophages Maybe Associated with Acute Myeloid Leukemia Survival and Prognosis

EphB4/ephrinB2 ephrinB1 Interaction Mediated Chronic Myelogenous Leukemia Mesenchymal Stromal Cells Osteogenic Differentiation in Vitro and In Vivo

CDKN2 Gene Deletion Impair Prognosis in Adult Ph+ Acute Lymphoblastic Leukemia Even in Tyrosine Kinase Inhibitors Era

LOXL2 Highly-Expressed Induce the Transition of Stromal Cells into Cancer-Associated Fibroblasts Which Maybe Involve in Myeloproliferative Neoplasms Progession

EphB4/EphrinB2 Contributes to Imatinib Resistance in Chronic Myeloid Leukemia Involved in Cytoskeletal Proteins

EphB4/ephrinB2 Interaction Mediate Chronic Myelogenous Leukemia Mesenchymal Stromal Cells Spreading and Osteogenic Differentiation

CDKN2 Gene Deletion As Poor Prognosis Predictor Involving in the Progression of Adult B-Lineage Acute Lymphoblastic Leukemia Patients

Therapeutic Immune Monitoring of Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors: Focus on CD4 + CD25 + t Cells

Inhibition of Siah2 Ubiquitin Ligase By Vitamin K3 Attenuates Hypoxia and Blocks K562-R Cells Resistance

Interferon Alpha May Improve the prognosis of Advanced Myeloproliferative Neoplasm Patients with JAK2V617F Mutations

The Prevalent, Features and Prognostic Impact of Deletion p16 in Patients with Adult Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only